银杏生物工程
DNA
10.27
-1.49
-12.67%
银杏生物工程
US · DNA
#3438 按市值排名
10.27
-1.49
-12.67%
实时 - 追踪5344个代码 - 心跳于82秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期(2026/Q3)披露持股的机构数量减少了3家。
- 机构持股总比例下降了7.0个百分点。
机构持股
- 机构持股比例
- 59.06% -6.99pp
- 机构数量
- 216 -3
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份,同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后;资金流向数据为每日更新。请将其作为方向性的交叉验证参考,而非精确的择时信号。
持股人类型
Mutual Fund35.57%
Individual/Insider14.96%
Hedge Fund13.85%
Family Office/Trust4.95%
Public Company2.29%
VC/PE Fund1.13%
Private Company0.79%
Insurance Company0.31%
Government Pension Fund0.17%
Other25.98%
主要股东 截至 2026-06-30
BlackRock
6.36% · 4.28M 股
Viking Global Investors LP
5.31% · 3.58M 股
Cascade Investment, L.L.C.
4.93% · 3.32M 股
Erste Asset Management GmbH
3.77% · 2.54M 股
Reshma Shetty
3.69% · 2.49M 股
Vanguard Capital Management, LLC
3.56% · 2.40M 股
Baillie Gifford
3.55% · 2.39M 股
Austin Che
3.54% · 2.39M 股
Bartholomew Canton
3.54% · 2.38M 股
Jason Kelly
3.50% · 2.36M 股
条形长度是相对于此处列出的最大股东而言,并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 18次买入 · 32次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Reshma Shetty | Founder, President, COO & Director | 3.69% |
| Austin Che | Founder, Head of Strategy & Treasurer | 3.54% |
| Bartholomew Canton | Founder, CTO & Secretary | 3.54% |
| Jason Kelly | Chief Executive Officer | 3.50% |
| Harry Sloan | Independent Director | 0.40% |
| Shyam Sankar | Independent Chairperson | 0.11% |
| Steven Coen | Chief Accounting Officer | 0.08% |
| Sriram Kosuri | Director | 0.04% |
| Christian O. Henry | Independent Director | 0.03% |
| Ross Fubini | Independent Director | 0.02% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-10-04 | Steven Coen | Chief Accounting Officer | Intent to Sell (Form 144) | -2,403 | $15.00 |
| 2026-09-16 | Austin Che | Founder, Head of Strategy & Treasurer | Intent to Sell (Form 144) | -2,200 | $7.29 |
| 2026-09-14 | Christian O. Henry | Independent Director | Open Market Disposition | -5,000 | $7.08 |
| 2026-08-23 | Steven Coen | Chief Accounting Officer | Derivative Exercise and Sale | -330 | $6.98 |
| 2026-08-23 | Steven Coen | Chief Accounting Officer | Intent to Sell (Form 144) | -330 | $6.98 |
| 2026-08-20 | Steven Coen | Chief Accounting Officer | Derivative Exercise and Retained | +413 | -- |
| 2026-08-16 | Austin Che | Founder, Head of Strategy & Treasurer | Intent to Sell (Form 144) | -2,200 | $6.66 |
| 2026-07-27 | Jason Kelly | Chief Executive Officer | Other Derivative Acquisition | +383,725 | -- |
| 2026-07-27 | Reshma Shetty | Founder, President, COO & Director | Other Derivative Acquisition | +319,332 | -- |
| 2026-07-27 | Bartholomew Canton | Founder, CTO & Secretary | Other Derivative Acquisition | +319,332 | -- |
| 2026-07-16 | Steven Coen | Chief Accounting Officer | Derivative Exercise and Sale | -752 | $7.90 |
| 2026-07-16 | Steven Coen | Chief Accounting Officer | Intent to Sell (Form 144) | -752 | $7.90 |
| 2026-07-15 | Steven Coen | Chief Accounting Officer | Derivative Exercise and Retained | +734 | -- |
| 2026-06-10 | Harry Sloan | Independent Director | Other Derivative Acquisition | +25,000 | -- |
| 2026-06-10 | Christian O. Henry | Independent Director | Other Derivative Acquisition | +25,000 | -- |
| 2026-06-10 | Ross Fubini | Independent Director | Other Derivative Acquisition | +25,000 | -- |
| 2026-06-10 | Sriram Kosuri | Director | Other Derivative Acquisition | +25,000 | -- |
| 2026-06-09 | Austin Che | Founder, Head of Strategy & Treasurer | Intent to Sell (Form 144) | -2,200 | $8.06 |
| 2026-05-21 | Steven Coen | Chief Accounting Officer | Derivative Exercise and Sale | -307 | $8.33 |
| 2026-05-21 | Steven Coen | Chief Accounting Officer | Intent to Sell (Form 144) | -307 | $8.33 |
Form 4 申报记录,每家公司显示最新的一批。"Other Derivative Acquisition"(其他衍生品获取)类目多为限制性股票/期权归属,并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:33 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
银杏生物工程 讨论区 0 条评论